Additionally, ASOs targeting KRAS also inhibited the tumor growth and invasiveness of HaP-T1 (from the BHP-induced hamster PC model) in a dose-dependent manner, whereas mismatched ASOs were not effective in inhibiting invasion (Morioka et al., 2005). This evidence concerns the gene KRAS and neoplasm.